To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-29

Study Completion Date

2019-04-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multicenter, Open-label, Parallel, Phase 2 Clinical Trial in 6 weeks for screening, once Investigational product injection, Follow up visit.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions(Phase 3)

NCT04606329

Breast Diseases

COMPLETED PHASE3

Early Imaging Biomarkers in NSCLC

NCT03121287

Thoracic Cancer

COMPLETED

Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive

NCT01668914

Breast Cancer

COMPLETED PHASE3

Photoacoustic Lymph Node Imaging

NCT03931655

Breast Cancer

TERMINATED

Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer

NCT00450723

Breast Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate the efficacy and safety of LuminoMark inj. (Conc. for fluorescence) localization in patients with nonpalpable breast lesions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LuminoMark inj. 0.1mL

Injection LuminoMark inj. 0.1mL once in this study.

Group Type EXPERIMENTAL

LuminoMark inj. 0.1mL

Intervention Type DRUG

Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.

LuminoMark inj. 0.2mL

Injection LuminoMark inj. 0.2mL once in this study.

Group Type EXPERIMENTAL

LuminoMark inj. 0.2mL

Intervention Type DRUG

Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.

Charcotrace Inj.

Charcotrace Inj. about 0.3\~1mL

Group Type ACTIVE_COMPARATOR

Charcotrace Inj.

Intervention Type DRUG

Injection Charcotrace Inj. about 0.3\~1mL once in this study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LuminoMark inj. 0.1mL

Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.

Intervention Type DRUG

LuminoMark inj. 0.2mL

Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.

Intervention Type DRUG

Charcotrace Inj.

Injection Charcotrace Inj. about 0.3\~1mL once in this study.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LuminoMark inj.(Conc. for fluorescence) 0.1mL LuminoMark inj.(Conc. for fluorescence) 0.2mL Charcotrace Injection(Activated Charcoal 40mg/1ml)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Female, 19 years ≤ age ≥ 80 years
2. Those who be expected to do operation about non palpable breast lesion excision
3. Those who have lesion vial mammography and breast ultrasound
4. Written consent voluntarily to participate in this clinical trial

Exclusion Criteria

1. Patients who be expected to do mastectomy
2. Patients with multiple tumor or diffuse microcalcification
3. Patients who have ink on invasive cancer or ductal carcinoma in situ despite 3 times local resection
4. Patients who were treated with moderate to severe radiotherapy
5. Patients who were treated with neoadjuvant Chemotherapy
6. Patients with active invading skin connective tissue disease
7. Patients with local progressing breast cancer or inflammatory local progressing breast cancer
8. Patients who have an allergy to investigational product or any of the component with the Investigational product
9. Patients who disagree about contraception for this clinical trial
10. A pregnant women or lactating women
11. Patients who participated in other clinical trials within the past 12 weeks from the date of informed consent
12. Patients who investigators determines unsuitable for this clinical trial

Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No